Condensation of fluconazole and zinc undecylanate particles using low-pressure RF plasma: a novel drug combination
Namık Bilici1, Ferhat Bozduman2
1Department of Medical Pharmacology, Faculty of Medicine, Karabük University, Karabük, Türkiye.
Background:
Fluconazole (FCZ), a triazole antifungal agent, is routinely used in the treatment of various Candida infections, including oropharyngeal, esophageal, vulvovaginal candidiasis, candidemia, and disseminated candidiasis. Despite its broad safety profile, superior efficacy, and favorable pharmacokinetics, resistance to FCZ is an increasing clinical challenge. Zinc undecylenate (ZU), derived from castor oil, is an established topical antifungal agent with additional dermatological protective and immunoendocrinological properties. Combining these two pharmacotherapeutic agents presents a promising approach to overcoming fungal resistance, preventing biofilm formation, and reducing recurrence rates.
Methods:
In this study, powdered ZU was condensed with powdered FCZ using low-pressure radiofrequency plasma (LPRFP). This plasma-assisted approach enabled the creation of a compound with sequential antifungal mechanisms. The condensed FCZ-ZU product was characterized and validated using nuclear magnetic resonance (NMR), optical emission spectrometry (OES), scanning electron microscopy (SEM), zeta potential, and particle size analyses. Statistical significance was determined using zeta potential and particle size data, with results evaluated at a threshold of p < 0.0001.
Results:
The plasma-condensed FCZ-ZU compound demonstrated distinct physicochemical properties compared to the parent FCZ and ZU powders. Characterization confirmed the structural modification and condensation process, while particle size and zeta potential analyses indicated significant differences, supporting the creation of a novel compound (p < 0.0001). The sequential mechanism of action between FCZ and ZU suggested enhanced antifungal efficacy, reduced likelihood of resistance development, and inhibition of biofilm formation.
Conclusions:
This study successfully demonstrated, for the first time, the plasma-assisted condensation of FCZ with ZU into a single antifungal preparation. The novel compound has the potential to shorten treatment duration, prevent relapse, and overcome resistance in persistent and recurrent mycosis infections. The findings highlight LPRFP as a promising method for combining multiple pharmacotherapeutic agents into innovative formulations with enhanced clinical potential.
Insights
A novel plasma-condensed compound of Fluconazole (FCZ) and Zinc undecylenate (ZU) offers a promising solution for combating antifungal resistance. This innovative preparation enhances efficacy and prevents biofilm formation in mycosis infections.
Area of Science:
- Mycology
- Pharmaceutical Sciences
- Materials Science
Background:
- Fluconazole (FCZ) is a key antifungal for Candida infections, but resistance is a growing concern.
- Zinc undecylenate (ZU) is a topical antifungal with dermatological benefits.
- Combining FCZ and ZU presents a strategy to overcome resistance and prevent recurrence.
Purpose of the Study:
- To develop a novel antifungal preparation by combining FCZ and ZU.
- To investigate the potential of plasma-assisted condensation for creating synergistic antifungal agents.
- To assess the physicochemical properties and potential efficacy of the combined compound.
Main Methods:
- Low-pressure radiofrequency plasma (LPRFP) was used to condense powdered ZU with powdered FCZ.
- The resulting FCZ-ZU compound was characterized using NMR, OES, SEM, zeta potential, and particle size analysis.
- Statistical significance was evaluated at p < 0.0001.
Main Results:
- Plasma condensation created a novel FCZ-ZU compound with distinct physicochemical properties.
- Characterization confirmed structural modification and successful condensation.
- Particle size and zeta potential analyses showed significant differences, indicating a new compound (p < 0.0001).
Conclusions:
- Plasma-assisted condensation successfully created a single, combined FCZ-ZU antifungal preparation.
- The novel compound demonstrates potential for enhanced efficacy, reduced resistance, and biofilm inhibition.
- This method offers a promising approach for developing innovative antifungal formulations to treat persistent mycosis.
More Related Videos
10:12Flash NanoPrecipitation for the Encapsulation of Hydrophobic and Hydrophilic Compounds in Polymeric Nanoparticles
Published on: January 7, 2019
12:05Preparation of Hydrophobic Metal-Organic Frameworks via Plasma Enhanced Chemical Vapor Deposition of Perfluoroalkanes for the Removal of Ammonia
Published on: October 10, 2013
